



DOCKET NO: M00765.70038.US


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Mark C. Poznansky et al.
Serial No.: 10/002,854
Confirmation No.: 3669
Filed: November 1, 2001
For: THE CaR RECEPTOR AS A MEDIATOR OF
MIGRATORY CELL CHEMOTAXIS AND/OR
CHEMOKINESIS
Examiner: Not yet assigned
Art Unit: 1623

RECEIVED
MAR 12 2003
TECH CENTER 1600/2900

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on the 28 day of February, 2003.


Michelle M. Quinn

Commissioner for Patents
Washington, D.C. 20231

Sir:


Transmitted herewith are the following documents:

- ☒ Information Disclosure Statement
- ☒ PTO Form 1449 with cited references
- ☒ Return Receipt Postcard


If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 720-3500, Boston, Massachusetts.

A check is not enclosed. If a fee is required, the Commissioner is hereby authorized to charge Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,
Mark C. Poznansky et al., *Applicant(s)*

By: 
Maria A. Trevisan, Reg. No. 48,207
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2211
Telephone: (617) 720-3500

Docket No. M00765.70038.US
Date: February 28, 2003
XNDDX




DOCKET NO: M00765.70038.US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Mark C. Poznansky et al.
Serial No.: 10/002,854
Confirmation No.: 3669
Filed: November 1, 2001
For: THE CaR RECEPTOR AS A MEDIATOR OF
MIGRATORY CELL CHEMOTAXIS AND/OR
CHEMOKINESIS
Examiner: Not yet assigned
Art Unit: 1623

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on the 28 day of February, 2003.


Michelle M. Quinn

Commissioner for Patents
Washington, D.C. 20231

**STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98**

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed before the mailing date of a first Office Action on the merits in the above-identified case. No fee or certification is required.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant hereby makes the following additional information of record in the above-identified application:

The Applicant would like to bring to the Examiner's attention the enclosed search report from a corresponding International or Foreign National Application:

International Search Report for PCT/US00/15440 published as WO 01/83546 (M00765.70027.WO).

PART III: Explanation of Non-English Language References and Remarks Concerning Other Information Cited

The following is a concise explanation of the relevance of each non-English language reference listed on the attached form PTO-1449 (modified):

The following are remarks concerning the other information cited:

PART IV: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.


By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.



An early and favorable action is hereby requested.

Respectfully submitted,
Mark C. Poznansky et al., *Applicant(s)*

By: 

Maria A. Trevisan, Reg. No. 48,207
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2211
Telephone: (617) 720-3500

Docket No. M00765.70038.US
Date: February 21, 2003
XNDDX



FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 10/002,854	ATTY. DOCKET NO.: M00/270038.US
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: November 1, 2001	CONFIRMATION NO.: 3668
		APPLICANT: Mark C. Poznansky, et al.	
		GROUP ART UNIT: 1623	EXAMINER: Not yet assigned
Sheet	1	of	2

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	A1	5,686,574		Moore et al.	11-11-1997
	A2	5,756,448		Moore et al.	05-26-1998

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
	B1	EP	0256989	A1	Univ Texas	02-24-1988	
	B2	EP	0852144	A2	Tufts College	07-08-1998	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
✓	C1	ADAMS, GB, et al., "Bone mineral contributes to Bone Marrow Hematopoiesis through the calcium sensing receptor." <i>American Society for Hematology, 2001 Annual Meeting, Orlando, FL, December 7-11, 2001. Abstract Only.</i>	
✓	C2	AIDA, K., et al., <i>Biochem. Biophys. Res. Commun.</i> 1995 Sep 14; 214(2):524-9 abstract only.	
✓	C3	BRUNDAGE RA, et al., <i>Science</i> 1991 Nov 1;254(5032):703-6. Abstract Only	
✓	C4	BURGER JA, et al., <i>Blood</i> 1999 Dec 1;94(11):3658-67. Abstract Only.	
✓	C5	CATAPANO AL., <i>Eur Heart J</i> 1997 Jan;18 Suppl A:A80-6. Abstract Only.	
✓	C6	CHATTOPADHYAY N, et al., <i>Brain Res Mol Brain Res</i> 2001 Aug 15;92(1-2):172-6. Abstract Only	
✓	C7	ELFERINK JG, et al., <i>Chem Biol Interact</i> 1995 Mar 30;95(1-2):203-14. Abstract Only.	
✓	C8	ELFERINK, JG et al., <i>Biochem Biophys Res Commun.</i> 1992, 182(2):864-9. Abstract Only.	
✓	C9	FERRARI MB, et al., <i>Dev Biol</i> 1999 Sep 15;213(2):269-82. Abstract Only.	
✓	C10	GANJU RK, et al., <i>J Biol Chem</i> 1998 Sep 4;273(36):23169-75.	
✓	C11	GENBANK ACCESSION D50855 Human mRNA for Ca-sensing receptor, complete cds. 23-JUN-1999	
✓	C12	GERSZTEN RE, et al., <i>Nature</i> 1999 Apr 22;398(6729):718-23, Abstract Only.	
✓	C13	GUINAMARD R., et al. <i>J Exp Med</i> 1999 May 3;189(9):1461-6. Abstract Only.	
✓	C14	HENRY PD., <i>Clin Invest Med</i> 1987 Nov;10(6):601-5. Abstract Only	
✓	C15	HERBETTE LG, et al., <i>Blood Press Suppl</i> 1998;2:10-7. Abstract Only.	
✓	C16	HOUSE MG, et al., <i>J Bone Miner Res</i> 1997 Dec;12(12):1959-70.	
✓	C17	HUANG HJ, et al., <i>J Leukoc Biol</i> 1997 May;61(5):624-9 Abstract Only	
✓	C18	JORDAN NJ, et al., <i>J Clin Invest</i> 1999 Oct;104(8):1061-9.	
✓	C19	KIM CH, et al., <i>J Clin Invest</i> 1999 Dec;104(12):1751-9.	
✓	C20	LASTER SM, et al. <i>J Immunol</i> 1988 Jul. 1, 141(1):221-7 Abstract Only	
✓	C21	LIU, L. et al., <i>J Immunol</i> 1999 Nov 15;163(10):5649-55. Abstract Only.	

✓	C22	MARASCO WA, et al., <i>Am J Pathol</i> 1980 Mar;98(3):749-68. Abstract Only.		
✓	C23	MARKS PW, et al., <i>J Cell Biol</i> 1990 Jan;110(1):43-52.		
✓	C24	MARRA, F., et al., <i>Hepatology</i> . 1999 Jan;29(1):140-8. Abstract Only.		
✓	C25	MCCOLL SR, et al., <i>J Immunol</i> 1999 Sep 1;163(5):2829-35. Abstract Only.		
✓	C26	MESHULAM T, et al., <i>J Immunol</i> . 1986 Sep 15;137(6):1954-60.		
✓	C27	MISHIMA T, et al., <i>Clin Exp Metastasis</i> 1998 Aug;16(6):541-50. Abstract Only.		
✓	C28	MURDOCH C, et al., <i>Cytokine</i> 1999 Sep;11(9):704-12. Abstract Only.		
✓	C29	MURDOCH C, et al., <i>Immunology</i> 1999 Sep;98(1):36-41. Abstract Only.		
✓	C30	NAYLER WG., <i>J Cardiovasc Pharmacol</i> 1999;33 Suppl 2:S7-11. Abstract Only.		
✓	C31	NIKOL S, et al., <i>Eur Heart J</i> 1997 Jan;18 Suppl A:A105-9. Abstract Only		
✓	C32	OLSZAK IT, et al., <i>J Clin Invest</i> 2000 May;105(9):1299-1305		
✓	C33	PAOLETTI R, et al., <i>Am J Cardiol</i> 1990 Nov 20;66(18):28H-31H. Abstract Only		
✓	C34	PAOLETTI R, et al., <i>Ann N Y Acad Sci</i> 1988;522:390-8. Abstract Only.		
✓	C35	PAOLETTI R, et al., <i>J Cardiovasc Pharmacol</i> 1995;25 Suppl 3:S6-10. Abstract Only.		
✓	C36	RAICU M, et al., <i>J Submicrosc Cytol Pathol</i> 1997 Jul;29(3):317-28 Abstract Only		
✓	C37	RIVIERE C., et al., <i>Blood</i> 1999 Mar 1;93(5):1511-23, Abstract Only.		
✓	C38	SCHMITZ G, et al. <i>Atherosclerosis</i> 1991 Jun;88(2-3):109-32 Abstract Only.		
✓	C39	SCHWARTZ J., <i>Fundam Clin Pharmacol</i> 1988;2(2):103-20. Abstract Only.		
✓	C40	SCHWEIZER RC, et al., <i>J Leukoc Biol</i> 1996 Mar;59(3):347-56.		
✓	C41	SHI H, et al., <i>FASEB J</i> 1996 Mar;10(4):491-501.		
✓	C42	SPERLING RI, et al., <i>J Clin Invest</i> 1993 Feb;91(2):651-60. Abstract Only.		
✓	C43	SUGIMOTO T, et al., <i>J Bone Miner Res</i> 1993 Dec;8(12):1445-52. Abstract Only		
✓	C44	SUZUKI H, et al., <i>Int Immunol</i> 1997 May;9(5):763-9. Abstract Only.		
✓	C45	TULENKO TN, et al., <i>Int J Cardiol</i> 1997 Dec 31;62 Suppl 2:S55-66. Abstract Only		
✓	C46	WEINSTEIN DB, et al., <i>Am J Cardiol</i> 1987 Jan 30;59(3):163B-172B. Abstract Only.		
✓	C47	YAMAGUCHI T, et al., <i>Endocrinology</i> 1998 Aug;139(8):3561-8. Abstract Only.		
✓	C48	YAMAGUCHI T, et al., <i>J Bone Miner Res</i> 1998 Sep;13(9):1390-7. Abstract Only.		
✓	C49	YAMAGUCHI T., et al., <i>Adv Pharmacol</i> 2000;47:209-53		
✓	C50	YOUN BS., et al., <i>Blood</i> 1999 Oct 1;94(7):2533-6. Abstract Only.		
✓	C51	ZHOU X., <i>Zhonghua Yi Xue Za Zhi</i> 1992 Jul;72(7):424-6, 447 Abstract Only.		

RECEIVED
MAR 12 2003
TECH CENTER 1600/2900

EXAMINER	DATE CONSIDERED
----------	-----------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]